"The new EURL Guidelines on sampling the food processing area and equipment for the detection of Listeria monocytogenes" - Léna Barre (ANSES, Frankreich)
"Listerien-Referenzlabor: Akademischer Luxus oder Public Health Erfordernis?", 19. Oktober 2012 (AGES, Graz)
Das Nationale Listerien-Referenzlabor ist innerhalb der AGES an das "Zentrum für lebensmittelbedingte Infektionskrankheiten" / Institut für medizinische Mikrobiologie und Hygiene in Graz übersiedelt. Zum Auftakt am neuen Standort veranstaltete die AGES dieses Fachgespräch, bei dem verschiedene Aspekte in Zusammenhang mit dem potentiellen Auftreten von Listerien aktuell beleuchtet wurden. Erstmals wurden zudem die neuen Richtlinien des Europäischen Referenzlabors (EU-RL) für Listeria monocytogenes zur Harmonisierung der Probennahme vorgestellt.
Dokumentation der Fachtagung mit Präsentationen:
http://www.ages.at/ages/ages-akademie/stakeholderveranstaltungen/graz-listerien-referenzlabor/
Presentation ai hce 2017 bob chen updated-3.0Kartik Vora
This document summarizes the results of a study comparing airborne exposure monitoring for surrogates and actual APIs during pharmaceutical manufacturing processes. Personal and static air samples were taken for both a surrogate (mannitol) and an API during various unit operations. Exposures for the API were generally higher than the surrogate, likely due to differences in work practices. The study concluded that while surrogate monitoring can indicate particulate containment effectiveness, it may not accurately represent actual employee API exposures due to variability in properties and work practices. API exposure monitoring is needed to confirm particulate containment and exposure levels. Work practices were found to significantly impact personal exposures and differences between surrogate and API results.
This presentation discusses pre-use post-sterilization integrity testing (PUPSIT) of sterile filters. It provides background on regulatory guidance for integrity testing critical filters before and after use. Masking studies were conducted where flawed filters were exposed to blocking solutions, and in some cases the flaws were able to mask and pass post-use integrity testing. The risk of masking was found to be highly dependent on process conditions like blocking rate and solution concentration. The presentation discusses considerations for final filtration assembly design to enable PUPSIT like using redundant filters and multi-purpose ports. It addresses challenges with maintaining sterility and pressure during PUPSIT.
The document summarizes key aspects of ISO 14644-1:2015, which provides the international standard for classifying air cleanliness in cleanrooms by particle concentration. It outlines the sampling and testing methodology used to measure airborne particle levels at different locations and classify cleanrooms into ISO classes based on particle size and concentration limits. Major changes in the updated 2015 standard include removing particle size classifications below 0.1 microns and above 5 microns, fixing the minimum number of required sampling locations based on cleanroom size, and eliminating the use of 95% confidence intervals in data analysis.
Expoquimia 2011: Forum Biotech - Daniel FernandezExpoquimia
Nanogap develops and manufactures novel nanomaterials for industries including coatings, plastics, textiles and electronics. It controls characteristics like particle size and morphology to customize products for applications. Nanogap recognizes regulatory challenges from a lack of basic science on nanomaterial safety. Its policy is to responsibly manage nanomaterials through a proactive approach of generating safety knowledge, transparency in sharing practices, and responsibility in overseeing products and processes. This includes collaborating with research groups on toxicity studies and participating in regulatory discussions.
This document discusses bioburden testing, which quantifies the number of microorganisms present on a medical device or pharmaceutical product. It outlines the purposes of bioburden testing such as acting as a quality control measure and determining necessary sterilization doses. The key steps of bioburden testing include sampling techniques, extraction methods, enumeration procedures like plate counting, and incubation. Regulations like CFR 21 and ISO 11737 provide standards for bioburden testing to ensure product quality and safety.
One Odour Unit-Precisely how can an Odour Unit be measured?mtingle
1. Precisely measuring odour units is challenging and can depend on several factors related to sampling methodology and analysis.
2. Not using proper sampling techniques like dilution for hot and humid sources can result in significant underestimation of odour levels, with predicted levels being over 10 times lower than actual levels.
3. Different sampling and analysis methods, as well as variables like panelist sensitivity, can result in odour measurements varying by factors of 3 to 16 times.
In this presentation from CPhi 2014, Elise Gallais outlines the guidelines for cleaning validation: and focuses on analytical methods and their validation.
This document provides information about soil and sediment sampling. It discusses basic principles of soil sampling including objectives of soil monitoring and parts of a monitoring plan. It covers site characterization, selection of sampling approach and factors that affect sample reliability. The document also addresses selection of area, sampling point, parameters and equipment for sampling. Finally, it discusses guidelines for handling and storage of soil samples including preservation techniques, as well as pre-treatment and extraction of contaminants from soil.
Presentation ai hce 2017 bob chen updated-3.0Kartik Vora
This document summarizes the results of a study comparing airborne exposure monitoring for surrogates and actual APIs during pharmaceutical manufacturing processes. Personal and static air samples were taken for both a surrogate (mannitol) and an API during various unit operations. Exposures for the API were generally higher than the surrogate, likely due to differences in work practices. The study concluded that while surrogate monitoring can indicate particulate containment effectiveness, it may not accurately represent actual employee API exposures due to variability in properties and work practices. API exposure monitoring is needed to confirm particulate containment and exposure levels. Work practices were found to significantly impact personal exposures and differences between surrogate and API results.
This presentation discusses pre-use post-sterilization integrity testing (PUPSIT) of sterile filters. It provides background on regulatory guidance for integrity testing critical filters before and after use. Masking studies were conducted where flawed filters were exposed to blocking solutions, and in some cases the flaws were able to mask and pass post-use integrity testing. The risk of masking was found to be highly dependent on process conditions like blocking rate and solution concentration. The presentation discusses considerations for final filtration assembly design to enable PUPSIT like using redundant filters and multi-purpose ports. It addresses challenges with maintaining sterility and pressure during PUPSIT.
The document summarizes key aspects of ISO 14644-1:2015, which provides the international standard for classifying air cleanliness in cleanrooms by particle concentration. It outlines the sampling and testing methodology used to measure airborne particle levels at different locations and classify cleanrooms into ISO classes based on particle size and concentration limits. Major changes in the updated 2015 standard include removing particle size classifications below 0.1 microns and above 5 microns, fixing the minimum number of required sampling locations based on cleanroom size, and eliminating the use of 95% confidence intervals in data analysis.
Expoquimia 2011: Forum Biotech - Daniel FernandezExpoquimia
Nanogap develops and manufactures novel nanomaterials for industries including coatings, plastics, textiles and electronics. It controls characteristics like particle size and morphology to customize products for applications. Nanogap recognizes regulatory challenges from a lack of basic science on nanomaterial safety. Its policy is to responsibly manage nanomaterials through a proactive approach of generating safety knowledge, transparency in sharing practices, and responsibility in overseeing products and processes. This includes collaborating with research groups on toxicity studies and participating in regulatory discussions.
This document discusses bioburden testing, which quantifies the number of microorganisms present on a medical device or pharmaceutical product. It outlines the purposes of bioburden testing such as acting as a quality control measure and determining necessary sterilization doses. The key steps of bioburden testing include sampling techniques, extraction methods, enumeration procedures like plate counting, and incubation. Regulations like CFR 21 and ISO 11737 provide standards for bioburden testing to ensure product quality and safety.
One Odour Unit-Precisely how can an Odour Unit be measured?mtingle
1. Precisely measuring odour units is challenging and can depend on several factors related to sampling methodology and analysis.
2. Not using proper sampling techniques like dilution for hot and humid sources can result in significant underestimation of odour levels, with predicted levels being over 10 times lower than actual levels.
3. Different sampling and analysis methods, as well as variables like panelist sensitivity, can result in odour measurements varying by factors of 3 to 16 times.
In this presentation from CPhi 2014, Elise Gallais outlines the guidelines for cleaning validation: and focuses on analytical methods and their validation.
This document provides information about soil and sediment sampling. It discusses basic principles of soil sampling including objectives of soil monitoring and parts of a monitoring plan. It covers site characterization, selection of sampling approach and factors that affect sample reliability. The document also addresses selection of area, sampling point, parameters and equipment for sampling. Finally, it discusses guidelines for handling and storage of soil samples including preservation techniques, as well as pre-treatment and extraction of contaminants from soil.
This document provides an overview of the ISO 16140 series of standards for validation and verification of microbiology methods. It discusses the development of the standards by Working Group 3, which involved over 100 experts from 23 countries. The standards address validation of reference methods, alternative methods, single laboratory validation, interlaboratory validation, and confirmation methods. Validation and verification are important to demonstrate that a method performs according to its specifications and is fit for its intended use when implemented in other laboratories.
The revised EU-GMP Annex 1 places a stronger emphasis on quality risk management, contamination control strategies, and aseptic processing. It requires regular review and documentation of risk assessments, staff training, use of rapid microbiological identification methods, strengthened environmental and personnel monitoring programs, and testing of container integrity under distribution conditions. All areas must have alarms for critical utility parameters like differential pressure. Facilities must implement these changes before the revised Annex 1 comes into effect on August 25, 2023.
The document discusses environmental monitoring programs in clean rooms and aseptic processing areas. It describes the purpose of monitoring to control microbial and particle contamination and prevent release of contaminated products. Key aspects covered include viable and non-viable monitoring of air, surfaces, personnel and drains using methods like air sampling, surface swabbing and particle counting. It provides classification standards and action limits for contamination and validation procedures for HVAC systems. Personnel are identified as the main challenge to control in aseptic processing.
What is likely to go into the revised Annex 1, including:
Terminal sterilisation vs aseptic processing
WFI produced by reverse osmosis
Guidance for media simulation trials
This remains speculative
The document discusses proposed changes to Annex 1 regarding viable monitoring of cleanrooms. It notes that Annex 1 will now require continuous monitoring throughout critical processes, rather than interval sampling. This reflects a shift from air sampling to real-time air monitoring. Continuous active air monitors are presented as able to meet the new Annex 1 requirements, capturing transient events better than settle plates. The document discusses various active air monitoring devices and their particle collection capabilities compared to traditional samplers. Real-time microbial monitoring using laser induced fluorescence is also proposed as an alternative to growth-based methods.
The document discusses changes made in the recent revisions of ISO 14644-1 and ISO 14644-2, which provide standards for cleanroom classification and monitoring. Key changes include new tables for determining the required number of sampling locations, removal of requirements to evaluate statistical confidence limits for some samples, and emphasis on using particle counters calibrated according to ISO 21501-4. The presentation also describes the purpose and requirements of cleanroom monitoring standards ISO 14644-2, including defining terms like monitoring, continuous monitoring, and sequential monitoring.
The document discusses regulatory perspectives on cleaning and contamination control from an inspector of the Therapeutic Goods Administration in Australia. It covers current GMP requirements, future GMP developments, observed good practices in contamination control, and common deficiencies found in inspections. Some key points include that contamination control strategies should be risk-based and rely on quality risk management principles. Inspections often find deficiencies in assessing intrinsic hazards of products and processes, in the design of facilities and equipment to control contamination risks, and in validation of cleaning processes.
Presentation: Cleaning and Contamination Control: A regulatory perspectiveTGA Australia
The document discusses regulatory perspectives on cleaning and contamination control from an inspector of the Therapeutic Goods Administration in Australia. It covers current GMP requirements, future GMP developments, observed good practices in contamination control, and common deficiencies found in inspections. Some key points include that contamination control strategies should be risk-based and rely on quality risk management principles. Inspections often find deficiencies in assessing intrinsic hazards of products and processes, in the design of facilities and equipment to control contamination risks, and in validation of cleaning processes.
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...Merck Life Sciences
Biopharmaceutical manufacturing capacities have expanded dramatically which has resulted in an increased demand for single-use systems (SUS) as they have their own advantages. Although SUS are well established in the biopharmaceutical industry there is limited guidance on regulatory expectations. Please attend the webinar to learn more!
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...MilliporeSigma
Biopharmaceutical manufacturing capacities have expanded dramatically which has resulted in an increased demand for single-use systems (SUS) as they have their own advantages. Although SUS are well established in the biopharmaceutical industry there is limited guidance on regulatory expectations. Please attend the webinar to learn more!
This document discusses environmental microbial monitoring (EMM) in cleanrooms and pharmaceutical facilities. It provides an overview of EMM purposes and regulations, who performs EMM, what areas are monitored, sampling plans and methods used. Key points covered include:
- EMM determines microbial and particulate levels to ensure cleanroom quality and identify contamination sources.
- Quality Control and Assurance departments perform EMM to demonstrate safety and ensure GMP compliance.
- Non-viable air, viable air and surface samples are monitored from areas like personnel, equipment and facilities.
- Sampling frequency, sites and methods like air samplers, settle plates, contact plates and swabbing are discussed in accordance with regulations like USP 39
Aseptic Process Sampling to address Risk of Contamination & Containment in co...Merck Life Sciences
In this webinar, you will learn:
- The challenges tied to contamination control within a biopharmaceutical environment.
- What closed processing is, and how sampling solutions are an integral component towards that end.
- Advantages of sterile sampling from both a technical and economical viewpoint; with the review of a technical study confirming contamination risk reduction and total cost of ownership.
- Recommendations and requirements stated by these major regulatory authorities around the monitoring of the manufacturing process with the execution of sampling.
Detailed description:
Biopharmaceutical manufacturers are required to ensure drug product quality attributes for patient safety. Strong contamination control strategies should be considered early in process design, and have direct influence on the production environment and equipment selection.
Sampling at each step is a critical component in maintaining a contamination control strategy. Regulators are critical in the sampling process, as it predicts the state of the product or process, and needs to be Representative. A case study will be presented that demonstrates a closed, robust sampling solution capable of maintaining a sterile flow path when challenged with Brevundimonas diminuta. The sampling option you select can help support your goal in achieving a closed process, improving your risk mitigation strategy and product safety.
Aseptic Process Sampling to address Risk of Contamination & Containment in co...MilliporeSigma
Watch this webinar here: bit.ly/asepticwebinar2020
In this webinar, you will learn:
- The challenges tied to contamination control within a biopharmaceutical environment.
- What closed processing is, and how sampling solutions are an integral component towards that end.
- Advantages of sterile sampling from both a technical and economical viewpoint; with the review of a technical study confirming contamination risk reduction and total cost of ownership.
- Recommendations and requirements stated by these major regulatory authorities around the monitoring of the manufacturing process with the execution of sampling.
Detailed description:
Biopharmaceutical manufacturers are required to ensure drug product quality attributes for patient safety. Strong contamination control strategies should be considered early in process design, and have direct influence on the production environment and equipment selection.
Sampling at each step is a critical component in maintaining a contamination control strategy. Regulators are critical in the sampling process, as it predicts the state of the product or process, and needs to be Representative. A case study will be presented that demonstrates a closed, robust sampling solution capable of maintaining a sterile flow path when challenged with Brevundimonas diminuta. The sampling option you select can help support your goal in achieving a closed process, improving your risk mitigation strategy and product safety.
This document summarizes production processes for phosphoric acid. It describes three main wet processes that use sulphuric acid to decompose phosphate rock: the dihydrate, hemihydrate, and di-hemihydrate (double stage) processes. These processes differ in the form of the resulting calcium sulphate byproduct - dihydrate, hemihydrate, or a combination. The document provides an overview of the raw materials, chemical reactions, production equipment and methods, emissions controls, and byproduct handling for phosphoric acid production.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMilliporeSigma
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
Should we be testing endoscopes? One life - Central Sterilising Club (csc) ...OneLife SA
The use of contaminated endoscopes can lead to patient-to-patient transmission of pathogens and infections. Studies evaluated cleanliness of patient-ready scopes after reprocessing and revealed between 10% and 30% of residual contamination.
Should therefore surveillance be standardized?
Pmtc good cleaning validation practiceRamy Mostafa
The document provides an overview of regulatory guidance and best practices for cleaning validation in the pharmaceutical industry. It discusses the origins of commonly used acceptance limits for cleaning validation of 0.001 dose and 10 ppm. It also outlines a lifecycle approach to cleaning validation involving stages of process design, process qualification through testing, and continued process verification. Automated and manual cleaning methods are described along with considerations for each.
The document discusses seed sampling and testing procedures. It explains that obtaining a representative sample is crucial, as test results can only reflect the quality of the sample. It describes different types of samples taken from a seed lot, including primary samples, composite samples, submitted samples, and working samples. The document outlines equipment and methods used for sampling, including deep bin samplers, triers, and hand sampling. It discusses dividing samples for testing in the laboratory and storing samples. Finally, it summarizes seed testing objectives and procedures, including receiving samples, moisture testing, preparing working samples, conducting routine tests, and maintaining records.
Wie das italienische Gesundheitsministerium am 12.9.2014 der Europäischen Kommission mitteilte, wurde der Kleine Bienenstockkäfer (Aethina tumida, engl. Small hive beetle) in Süditalien, in der Nähe des Hafens von Gioia Tauro in der Provinz Reggio Calabria, in einem Ableger (= kleines Bienenvolk) nachgewiesen. Es wurden erwachsene Käfer und Larven gefunden. Die befallenen Bienenstöcke wurden vernichtet. Dr. Irmgard Derakhshifar von der Abteilung Bienenkunde und Bienenschutz präsentierte bei der Wanderlehrerfachtagung in Tirol den aktuellen Wissensstand: http://www.ages.at/ages/presse/pressemeldungen/kleiner-bienenstockkaefer-in-italien-nachgewiesen/
Das Projekt "Bioenergy-Silphium" erforscht die Erhöhung der Biomasseproduktion durch Silphium perfoliatum L. zur energetischen Verwertung in Österreich.
Bei der Erzeugung von erneuerbarer Energie spielt die Biomasse eine wesentliche Rolle. Werden zur Rohstoffgewinnung Acker- oder Grünlandflächen verwendet, ergibt sich zwischen Futter- bzw. Nahrungsmittelproduktion und der Biomasseerzeugung ein gewisses Konfliktpotential. Um dieses zu minimieren, braucht es Alternativen. Silphium perfoliatum L. könnte so eine Alternative sein, da sie eine ertragsstarke, mehrjährige, anspruchslose Pflanze ist die auch auf Nichtackerflächen (Brach-, Kommunalflächen, ehemaligen Abraum- bzw. Deponieflächen, etc.) und erosionsgefährdeten Flächen (u.a. Hanglagen) kultiviert werden kann. Damit ließen sich die verfügbaren Flächen für die Produktion von Biomasse-Rohstoffen erhöhen, ohne die Flächen für die Futter- und Nahrungsmittelproduktion einzuschränken.
In dieser Präsentation vom 4. Mai 2014 stellt Josef Mayr Zwischenergebnissen des Projektes Bioenergy-Silphium und Beflugerhebung am Standort Wien dar.
More Related Content
Similar to "The new EURL Guidelines on sampling the food processing area and equipment for the detection of Listeria monocytogenes" - Léna Barre (ANSES, Frankreich)
This document provides an overview of the ISO 16140 series of standards for validation and verification of microbiology methods. It discusses the development of the standards by Working Group 3, which involved over 100 experts from 23 countries. The standards address validation of reference methods, alternative methods, single laboratory validation, interlaboratory validation, and confirmation methods. Validation and verification are important to demonstrate that a method performs according to its specifications and is fit for its intended use when implemented in other laboratories.
The revised EU-GMP Annex 1 places a stronger emphasis on quality risk management, contamination control strategies, and aseptic processing. It requires regular review and documentation of risk assessments, staff training, use of rapid microbiological identification methods, strengthened environmental and personnel monitoring programs, and testing of container integrity under distribution conditions. All areas must have alarms for critical utility parameters like differential pressure. Facilities must implement these changes before the revised Annex 1 comes into effect on August 25, 2023.
The document discusses environmental monitoring programs in clean rooms and aseptic processing areas. It describes the purpose of monitoring to control microbial and particle contamination and prevent release of contaminated products. Key aspects covered include viable and non-viable monitoring of air, surfaces, personnel and drains using methods like air sampling, surface swabbing and particle counting. It provides classification standards and action limits for contamination and validation procedures for HVAC systems. Personnel are identified as the main challenge to control in aseptic processing.
What is likely to go into the revised Annex 1, including:
Terminal sterilisation vs aseptic processing
WFI produced by reverse osmosis
Guidance for media simulation trials
This remains speculative
The document discusses proposed changes to Annex 1 regarding viable monitoring of cleanrooms. It notes that Annex 1 will now require continuous monitoring throughout critical processes, rather than interval sampling. This reflects a shift from air sampling to real-time air monitoring. Continuous active air monitors are presented as able to meet the new Annex 1 requirements, capturing transient events better than settle plates. The document discusses various active air monitoring devices and their particle collection capabilities compared to traditional samplers. Real-time microbial monitoring using laser induced fluorescence is also proposed as an alternative to growth-based methods.
The document discusses changes made in the recent revisions of ISO 14644-1 and ISO 14644-2, which provide standards for cleanroom classification and monitoring. Key changes include new tables for determining the required number of sampling locations, removal of requirements to evaluate statistical confidence limits for some samples, and emphasis on using particle counters calibrated according to ISO 21501-4. The presentation also describes the purpose and requirements of cleanroom monitoring standards ISO 14644-2, including defining terms like monitoring, continuous monitoring, and sequential monitoring.
The document discusses regulatory perspectives on cleaning and contamination control from an inspector of the Therapeutic Goods Administration in Australia. It covers current GMP requirements, future GMP developments, observed good practices in contamination control, and common deficiencies found in inspections. Some key points include that contamination control strategies should be risk-based and rely on quality risk management principles. Inspections often find deficiencies in assessing intrinsic hazards of products and processes, in the design of facilities and equipment to control contamination risks, and in validation of cleaning processes.
Presentation: Cleaning and Contamination Control: A regulatory perspectiveTGA Australia
The document discusses regulatory perspectives on cleaning and contamination control from an inspector of the Therapeutic Goods Administration in Australia. It covers current GMP requirements, future GMP developments, observed good practices in contamination control, and common deficiencies found in inspections. Some key points include that contamination control strategies should be risk-based and rely on quality risk management principles. Inspections often find deficiencies in assessing intrinsic hazards of products and processes, in the design of facilities and equipment to control contamination risks, and in validation of cleaning processes.
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...Merck Life Sciences
Biopharmaceutical manufacturing capacities have expanded dramatically which has resulted in an increased demand for single-use systems (SUS) as they have their own advantages. Although SUS are well established in the biopharmaceutical industry there is limited guidance on regulatory expectations. Please attend the webinar to learn more!
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...MilliporeSigma
Biopharmaceutical manufacturing capacities have expanded dramatically which has resulted in an increased demand for single-use systems (SUS) as they have their own advantages. Although SUS are well established in the biopharmaceutical industry there is limited guidance on regulatory expectations. Please attend the webinar to learn more!
This document discusses environmental microbial monitoring (EMM) in cleanrooms and pharmaceutical facilities. It provides an overview of EMM purposes and regulations, who performs EMM, what areas are monitored, sampling plans and methods used. Key points covered include:
- EMM determines microbial and particulate levels to ensure cleanroom quality and identify contamination sources.
- Quality Control and Assurance departments perform EMM to demonstrate safety and ensure GMP compliance.
- Non-viable air, viable air and surface samples are monitored from areas like personnel, equipment and facilities.
- Sampling frequency, sites and methods like air samplers, settle plates, contact plates and swabbing are discussed in accordance with regulations like USP 39
Aseptic Process Sampling to address Risk of Contamination & Containment in co...Merck Life Sciences
In this webinar, you will learn:
- The challenges tied to contamination control within a biopharmaceutical environment.
- What closed processing is, and how sampling solutions are an integral component towards that end.
- Advantages of sterile sampling from both a technical and economical viewpoint; with the review of a technical study confirming contamination risk reduction and total cost of ownership.
- Recommendations and requirements stated by these major regulatory authorities around the monitoring of the manufacturing process with the execution of sampling.
Detailed description:
Biopharmaceutical manufacturers are required to ensure drug product quality attributes for patient safety. Strong contamination control strategies should be considered early in process design, and have direct influence on the production environment and equipment selection.
Sampling at each step is a critical component in maintaining a contamination control strategy. Regulators are critical in the sampling process, as it predicts the state of the product or process, and needs to be Representative. A case study will be presented that demonstrates a closed, robust sampling solution capable of maintaining a sterile flow path when challenged with Brevundimonas diminuta. The sampling option you select can help support your goal in achieving a closed process, improving your risk mitigation strategy and product safety.
Aseptic Process Sampling to address Risk of Contamination & Containment in co...MilliporeSigma
Watch this webinar here: bit.ly/asepticwebinar2020
In this webinar, you will learn:
- The challenges tied to contamination control within a biopharmaceutical environment.
- What closed processing is, and how sampling solutions are an integral component towards that end.
- Advantages of sterile sampling from both a technical and economical viewpoint; with the review of a technical study confirming contamination risk reduction and total cost of ownership.
- Recommendations and requirements stated by these major regulatory authorities around the monitoring of the manufacturing process with the execution of sampling.
Detailed description:
Biopharmaceutical manufacturers are required to ensure drug product quality attributes for patient safety. Strong contamination control strategies should be considered early in process design, and have direct influence on the production environment and equipment selection.
Sampling at each step is a critical component in maintaining a contamination control strategy. Regulators are critical in the sampling process, as it predicts the state of the product or process, and needs to be Representative. A case study will be presented that demonstrates a closed, robust sampling solution capable of maintaining a sterile flow path when challenged with Brevundimonas diminuta. The sampling option you select can help support your goal in achieving a closed process, improving your risk mitigation strategy and product safety.
This document summarizes production processes for phosphoric acid. It describes three main wet processes that use sulphuric acid to decompose phosphate rock: the dihydrate, hemihydrate, and di-hemihydrate (double stage) processes. These processes differ in the form of the resulting calcium sulphate byproduct - dihydrate, hemihydrate, or a combination. The document provides an overview of the raw materials, chemical reactions, production equipment and methods, emissions controls, and byproduct handling for phosphoric acid production.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMilliporeSigma
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
Should we be testing endoscopes? One life - Central Sterilising Club (csc) ...OneLife SA
The use of contaminated endoscopes can lead to patient-to-patient transmission of pathogens and infections. Studies evaluated cleanliness of patient-ready scopes after reprocessing and revealed between 10% and 30% of residual contamination.
Should therefore surveillance be standardized?
Pmtc good cleaning validation practiceRamy Mostafa
The document provides an overview of regulatory guidance and best practices for cleaning validation in the pharmaceutical industry. It discusses the origins of commonly used acceptance limits for cleaning validation of 0.001 dose and 10 ppm. It also outlines a lifecycle approach to cleaning validation involving stages of process design, process qualification through testing, and continued process verification. Automated and manual cleaning methods are described along with considerations for each.
The document discusses seed sampling and testing procedures. It explains that obtaining a representative sample is crucial, as test results can only reflect the quality of the sample. It describes different types of samples taken from a seed lot, including primary samples, composite samples, submitted samples, and working samples. The document outlines equipment and methods used for sampling, including deep bin samplers, triers, and hand sampling. It discusses dividing samples for testing in the laboratory and storing samples. Finally, it summarizes seed testing objectives and procedures, including receiving samples, moisture testing, preparing working samples, conducting routine tests, and maintaining records.
Similar to "The new EURL Guidelines on sampling the food processing area and equipment for the detection of Listeria monocytogenes" - Léna Barre (ANSES, Frankreich) (20)
Wie das italienische Gesundheitsministerium am 12.9.2014 der Europäischen Kommission mitteilte, wurde der Kleine Bienenstockkäfer (Aethina tumida, engl. Small hive beetle) in Süditalien, in der Nähe des Hafens von Gioia Tauro in der Provinz Reggio Calabria, in einem Ableger (= kleines Bienenvolk) nachgewiesen. Es wurden erwachsene Käfer und Larven gefunden. Die befallenen Bienenstöcke wurden vernichtet. Dr. Irmgard Derakhshifar von der Abteilung Bienenkunde und Bienenschutz präsentierte bei der Wanderlehrerfachtagung in Tirol den aktuellen Wissensstand: http://www.ages.at/ages/presse/pressemeldungen/kleiner-bienenstockkaefer-in-italien-nachgewiesen/
Das Projekt "Bioenergy-Silphium" erforscht die Erhöhung der Biomasseproduktion durch Silphium perfoliatum L. zur energetischen Verwertung in Österreich.
Bei der Erzeugung von erneuerbarer Energie spielt die Biomasse eine wesentliche Rolle. Werden zur Rohstoffgewinnung Acker- oder Grünlandflächen verwendet, ergibt sich zwischen Futter- bzw. Nahrungsmittelproduktion und der Biomasseerzeugung ein gewisses Konfliktpotential. Um dieses zu minimieren, braucht es Alternativen. Silphium perfoliatum L. könnte so eine Alternative sein, da sie eine ertragsstarke, mehrjährige, anspruchslose Pflanze ist die auch auf Nichtackerflächen (Brach-, Kommunalflächen, ehemaligen Abraum- bzw. Deponieflächen, etc.) und erosionsgefährdeten Flächen (u.a. Hanglagen) kultiviert werden kann. Damit ließen sich die verfügbaren Flächen für die Produktion von Biomasse-Rohstoffen erhöhen, ohne die Flächen für die Futter- und Nahrungsmittelproduktion einzuschränken.
In dieser Präsentation vom 4. Mai 2014 stellt Josef Mayr Zwischenergebnissen des Projektes Bioenergy-Silphium und Beflugerhebung am Standort Wien dar.
Informationsbroschüre über das West Nil Virus: Ursprung, Übertragungswege, Symptome, Inkubationszeit, Behandlung, Tipps zur Vermeidung von Stechmückenstichen sowie Anlaufstellen. Link zum AGES-Schwerpunkt: Vektorübertragene Krankheiten - West Nil Virus: http://www.ages.at/ages/gesundheit/vektoruebertragene-krankheiten/west-nil-fieber/
Beim Symposium zum 6. Europäischen Antibiotikatag am 15. November 2013 im Festsaal des Gesundheitsministeriums (BMG) wurden die jüngsten Entwicklungstrends in der Human- und Veterinärmedizin sowie der Österreichische Aktionsplan gegen Antibiotika-Resistenzen (NAP-AMR) präsentiert. Ziel der gemeinsamen Bemühungen der Bereiche Human- und Veterinärmedizin sowie Lebensmittelsicherheit ist es, die Entstehung und Ausbreitung von antimikrobiellen Resistenzen nachhaltig zu vermindern, um die Wirksamkeit der vorhandenen antimikrobiell wirksamen Substanzen zu erhalten und die Qualität der antimikrobiellen Therapien zu fördern. Die AGES-ExpertInnen arbeiten an der Erstellung des AURES-Resistenzberichts mit, um für Österreich repräsentative Daten zur antimikrobiellen Resistenz und Entwicklungstrends zum Verbrauch antimikrobieller Substanzen darstelle zu können. Außerdem erhebt die AGES die verkauften Mengen von Antibiotika in der Nutztiermedizin seit 2010: In Österreich wurden 2012 insgesamt 53,22 Tonnen Antibiotika an TierärztInnen für den Einsatz in der Veterinärmedizin verkauft. Der Trend ist insgesamt rückläufig. Link: http://www.ages.at/ages/ages-akademie/programm/15112013-symposium-zum-6-europaeischer-antibiotikatag/
Beim Symposium zum 6. Europäischen Antibiotikatag am 15. November 2013 im Festsaal des Gesundheitsministeriums (BMG) wurden die jüngsten Entwicklungstrends in der Human- und Veterinärmedizin sowie der Österreichische Aktionsplan gegen Antibiotika-Resistenzen (NAP-AMR) präsentiert. Ziel der gemeinsamen Bemühungen der Bereiche Human- und Veterinärmedizin sowie Lebensmittelsicherheit ist es, die Entstehung und Ausbreitung von antimikrobiellen Resistenzen nachhaltig zu vermindern, um die Wirksamkeit der vorhandenen antimikrobiell wirksamen Substanzen zu erhalten und die Qualität der antimikrobiellen Therapien zu fördern. Die AGES-ExpertInnen arbeiten an der Erstellung des AURES-Resistenzberichts mit, um für Österreich repräsentative Daten zur antimikrobiellen Resistenz und Entwicklungstrends zum Verbrauch antimikrobieller Substanzen darstelle zu können. Außerdem erhebt die AGES die verkauften Mengen von Antibiotika in der Nutztiermedizin seit 2010: In Österreich wurden 2012 insgesamt 53,22 Tonnen Antibiotika an TierärztInnen für den Einsatz in der Veterinärmedizin verkauft. Der Trend ist insgesamt rückläufig. Link: http://www.ages.at/ages/ages-akademie/programm/15112013-symposium-zum-6-europaeischer-antibiotikatag/
AGES-Experten zur gesundheitlichen Bedeutung von Neobiota für Mensch, Tier und Pflanze: Nicht heimische Arten (Neobiota) können negative Auswirkungen auf die Gesundheit von Menschen, Tieren und Pflanzen haben. Für die betroffenen Menschen bedeutet dies eine verminderte Lebensqualität, zudem entstehen volkswirtschaftliche Kosten(Behandlungen, Krankenstände). Zu den Folgen für den Menschen kommen negative Auswirkungen aus der Sicht des Naturschutzes, aber auch für die Land- und Forstwirtschaft und die Fischerei. Die AGES-Experten Swen Follak (Pflanzengesundheit und Allergene für Mensch), Rudolf Moosbeckhofer (Bienengesundheit) und Peter Hufnagl (Gesundheit Mensch) gaben bei der dritten Österreichischen Neobiota-Tagung einen Überblick über aktuelle Kenntnisse und diskutiert Handlungserfordernisse im Umgang mit gesundheitlich relevanten nicht heimischen Arten in Österreich: http://www.ages.at/ages/presse/pressemeldungen/ages-experten-zu-neobiota/
AGES-Experten zur gesundheitlichen Bedeutung von Neobiota für Mensch, Tier und Pflanze: Nicht heimische Arten (Neobiota) können negative Auswirkungen auf die Gesundheit von Menschen, Tieren und Pflanzen haben. Für die betroffenen Menschen bedeutet dies eine verminderte Lebensqualität, zudem entstehen volkswirtschaftliche Kosten(Behandlungen, Krankenstände). Zu den Folgen für den Menschen kommen negative Auswirkungen aus der Sicht des Naturschutzes, aber auch für die Land- und Forstwirtschaft und die Fischerei. Die AGES-Experten Swen Follak (Pflanzengesundheit und Allergene für Mensch), Rudolf Moosbeckhofer (Bienengesundheit) und Peter Hufnagl (Gesundheit Mensch) gaben bei der dritten Österreichischen Neobiota-Tagung einen Überblick über aktuelle Kenntnisse und diskutiert Handlungserfordernisse im Umgang mit gesundheitlich relevanten nicht heimischen Arten in Österreich: http://www.ages.at/ages/presse/pressemeldungen/ages-experten-zu-neobiota/
AGES-Experten zur gesundheitlichen Bedeutung von Neobiota für Mensch, Tier und Pflanze: Nicht heimische Arten (Neobiota) können negative Auswirkungen auf die Gesundheit von Menschen, Tieren und Pflanzen haben. Für die betroffenen Menschen bedeutet dies eine verminderte Lebensqualität, zudem entstehen volkswirtschaftliche Kosten(Behandlungen, Krankenstände). Zu den Folgen für den Menschen kommen negative Auswirkungen aus der Sicht des Naturschutzes, aber auch für die Land- und Forstwirtschaft und die Fischerei. Die AGES-Experten Swen Follak (Pflanzengesundheit und Allergene für Mensch), Rudolf Moosbeckhofer (Bienengesundheit) und Peter Hufnagl (Gesundheit Mensch) gaben bei der dritten Österreichischen Neobiota-Tagung einen Überblick über aktuelle Kenntnisse und diskutiert Handlungserfordernisse im Umgang mit gesundheitlich relevanten nicht heimischen Arten in Österreich: http://www.ages.at/ages/presse/pressemeldungen/ages-experten-zu-neobiota/
Unsere Vision: Gesundheit für Mensch, Tier und Pflanze - Mit der Umsetzung des Wirkungsorientierten Unternehmenskonzepts (WUK) 2011 - 2015, das in enger Abstimmung mit den Eigentümerministerien (BMG/BMLFUW) vorbereitet wurde, wurde im Sommer 2012 fast auf den Tag genau zehn Jahre nach Gründung der Agentur für Gesundheit und Ernährungssicherheit (AGES) der zweite große Schritt vom "Amt" Richtung privatwirtschaftlich organisiertes Dienstleistungsunternehmen mit volkswirtschaftlichem Auftrag zu Gesundheit, Ernährungssicherheit und Ernährungssicherung vollzogen. Die AGES setzte die ab 2013 geltenden Vorgaben des Finanzministeriums (BMF) an alle Bundesministerien nach einer modernen, wirkungsorientierten Haushaltsführung frühzeitig um. Mit dem wirkungsorientierten Budget erfolgt eine transparente Darstellung des Einsatzes der Steuergelder gemessen am Wirkungserfolg, der durch Gesetze und den Eigentümer vorgegebenen Ziele. Mit dieser strategischen Neuausrichtung ist die AGES in Europa als ExpertInnenorganisation im Bereich der Untersuchung und Begutachtung, Risikobewertung / Risikokommunikation und Zulassung im Kreislauf Mensch-Tier-Pflanze-Boden über 2015 hinaus nachhaltig, wettbewerbsfähig und fit für die Zukunft positioniert. Link: http://www.ages.at/ages/ueber-uns/das-unternehmen/organisation/unternehmensstrategie/
The Austrian Agency for Health and Food Safety (AGES) is a government owned agency attached to the Federal Ministry for Health and to the Federal Ministry of Agriculture, Forestry, Environment and Water Management. AGES was established on the basis of a Federal law as a private entity (limited company) with a public service mission.
The business areas of AGES are Food Security, Food Safety, Animal health, Public Health, Medicines and Medical Devices, Radiation Protection, Statistics and Risk Assessment and Research and Capacity Building. AGES is responsible for food from soil to fork, effective control and prevention of epidemics for people, animals and plants and providing effective and safe pharmaceutical products.
AGES executes federal state tasks in the areas conducts research in the areas above mentioned. AGES is recognized as "research" and "non-profit" organization according to FP7 rules for participation.
AGES operates the federal laboratories related to food and feed safety, water analysis and radiation protection, the main diagnostic laboratories related to food safety and human health, animal health and plant health. AGES’s laboratories serve as national reference laboratories according to Regulation No. (EC) 882/2004, as national reference laboratories for animal diseases (OIE), as reference center’s for infectious diseases and as official laboratories for plant health, seeds and propagating material.
AGES employs approximately 1.350 persons, of whom more than 40% are scientists or experts with academic degrees (approx. 300 PhDs and 15 university professors) in nearly all disciplines related to food and health safety.
Contact:
DI. Mag. DDr. Alois Leidwein
Tel.: +43 (0)50 555 – 34853
E-Mail: alois.leidwein@ages.at
Homepage: http://www.ages.at/ages/en/research-international-cooperation/
Besuch von ECDC-Direktor im Public Health-Zentrum der IMED Wien: Marc Sprenger, Direktor des European Centre for Disease Prevention and Control (ECDC), war am 11. April 2013 zu Gast im Zentrum für anthropogene Infektionen des AGES Geschäftsfeldes "Öffentliche Gesundheit" in in Wien. Im Rahmen seines "Country visit" suchte er den fachlichen Austausch mit den AGES-ExpertInnen, interessierte sich für die Zuständigkeiten und die Rolle der AGES im österreichischen Gesundheitswesen.
MELISSA - Report
http://www.dafne.at/dafne_plus_homepage/index.php?section=dafneplus&content=result&come_from=&&search_fields[offer_number]=100472&search_fields[title_ger]=&search_fields[research_objective]=&search_fields[beauftragungsjahr]=&search_fields[antragsteller]=&search_fields[projektleiter]=&project_id=2909
Summary
The number of reports about honey bee colony losses or damages from many countries has increased over the last years. The potential causes are numerous and could differ case by case. According to the current knowledge, a single factor is rarely responsible. In fact, in many cases more likely a combination of etiological factors is involved, e.g. colony management and good apicultural practice, environmental and anthropogenic elements as well as honey bee pests and parasites.
In spring 2008 severe honey bee losses occurred in Germany (Rhine valley), in Italy and Slovenia during and after sowing of clothianidin coated maize seed with pneumatic seed drills. Further investigations in Germany proved the causal connection between the use of this seed dressing insecticide and the reported damages in honey bee colonies.
In order to assess the possible relevance of this problem to Austria, the project “Investigations in the incidence of bee losses in corn and oilseed rape growing areas of Austria and possible correlations with bee diseases and the use of insecticidal plant protection products” (acronym: “MELISSA”) was carried out in the years 2009 – 2011 on behalf of the Federal Ministry of Agriculture, Forestry, Environment and Water Management and the Austrian federal provinces. The aim of the project was to identify possible correlations between the incidence of honey bee losses in production areas of maize and oilseed rape and bee diseases or the use of plant protection products on the basis of field data.
Summing up, the results of the MELISSA-project give evidence that in Austria regional clustered bee damages had occurred in the years 2009 – 2011, which were frequently associated with the use of maize and oilseed pumpkin seeds coated with insecticides, as proved by residue analysis. The strong local component and the accumulation in areas with small-scale structured agriculture indicated special environmental conditions resulting in an increased exposition of honey bees to the identified insecticidal plant protection substances in the affected areas.
Regulatory measures to prevent honey bee losses due to the exposure of bees to insecticidal seed dressing substances have significantly improved the situation. However, repeatedly observed incidences of honey bee mortality in defined regions suggest their systematic correlation with local factors contributing to increased exposure of bees. In addition to considering environmental factors, all measures to mitigate risks have to be implemented invariably and with discipline.
Das Nationale Listerien-Referenzlabor ist innerhalb der AGES an das "Zentrum für lebensmittelbedingte Infektionskrankheiten" / Institut für medizinische Mikrobiologie und Hygiene in Graz übersiedelt. Zum Auftakt am neuen Standort veranstaltete die AGES dieses Fachgespräch, bei dem verschiedene Aspekte in Zusammenhang mit dem potentiellen Auftreten von Listerien aktuell beleuchtet wurden. Erstmals wurden zudem die neuen Richtlinien des Europäischen Referenzlabors (EU-RL) für Listeria monocytogenes zur Harmonisierung der Probennahme vorgestellt.
Dokumentation der Fachtagung mit Präsentationen:
http://www.ages.at/ages/ages-akademie/stakeholderveranstaltungen/graz-listerien-referenzlabor/
Amtstierärztliche Weiterbildung 2012 - Diese Weiterbildungsverranstaltung wurde in Kombination mit dem "Symposium zum Europäischen Antibiotikatag 2012" angeboten. Der thematische Focus des Vortragsteils lag dabei auf Vector-borne diseases in Europa im Allgemeinen sowie der Situation in Österreich im Speziellen. Des weiteren wurden erste Ergebnisse eines Forschungsprojektes zum Thema BTV Risikobewertung und Modellierung präsentiert. Hier geht's zur Dokumentation: http://www.ages.at/ages/ages-akademie/programm/dokumentation/programm-2012/14112012-amtstieraerztliche-weiterbildung-2012/
Anlässlich des 10-jährigen Bestehens der AGES und der 5-jährigen Kooperation mit dem deutschen Bundesinstitut für Risikobewertung (BfR) fanden zwei Spezialveranstaltungen zum Thema Nahrungsergänzungsmittel (NEM) statt, bei der die bisher umfassendste Erhebung zum Thema im deutschen Sprachraum exklusiv präsentiert wurde. Risiken und Nutzen von NEM wurden aus Sicht der Lebensmittel- & Arzneimittelsicherheit, Risikobewertung & Risikokommunikation, die den Verbraucherinteressen gerecht wird, betrachtet. Anbei die Dokumentation der beiden Fachtagungen mit den Vorträgen und Präsentationen:
1. AGES-BfR-Forum "Nahrungsergänzungsmittel: Nutzen und Risiko", 30. Mai 2012 (AGES, Wien)
http://www.ages.at/ages/ages-akademie/stakeholderveranstaltungen/wien-nahrungsergaenzungsmittel/
14. BfR-Forum Verbraucherschutz Nahrungsergänzungsmittel "Notwendig, Luxus oder gesundheitliches Risiko?", 10./11. Oktober 2012 (BfR, Berlin)
http://www.bfr.bund.de/de/veranstaltung/14__bfr_forum_verbraucherschutz__nahrungsergaenzungsmittel_-129397.html
"Listerien-Referenzlabor: Akademischer Luxus oder Public Health Erfordernis?", 19. Oktober 2012 (AGES, Graz)
Das Nationale Listerien-Referenzlabor ist innerhalb der AGES an das "Zentrum für lebensmittelbedingte Infektionskrankheiten" / Institut für medizinische Mikrobiologie und Hygiene in Graz übersiedelt. Zum Auftakt am neuen Standort veranstaltete die AGES dieses Fachgespräch, bei dem verschiedene Aspekte in Zusammenhang mit dem potentiellen Auftreten von Listerien aktuell beleuchtet wurden. Erstmals wurden zudem die neuen Richtlinien des Europäischen Referenzlabors (EU-RL) für Listeria monocytogenes zur Harmonisierung der Probennahme vorgestellt.
Dokumentation der Fachtagung mit Präsentationen:
http://www.ages.at/ages/ages-akademie/stakeholderveranstaltungen/graz-listerien-referenzlabor/
"Listerien-Referenzlabor: Akademischer Luxus oder Public Health Erfordernis?", 19. Oktober 2012 (AGES, Graz)
Das Nationale Listerien-Referenzlabor ist innerhalb der AGES an das "Zentrum für lebensmittelbedingte Infektionskrankheiten" / Institut für medizinische Mikrobiologie und Hygiene in Graz übersiedelt. Zum Auftakt am neuen Standort veranstaltete die AGES dieses Fachgespräch, bei dem verschiedene Aspekte in Zusammenhang mit dem potentiellen Auftreten von Listerien aktuell beleuchtet wurden. Erstmals wurden zudem die neuen Richtlinien des Europäischen Referenzlabors (EU-RL) für Listeria monocytogenes zur Harmonisierung der Probennahme vorgestellt.
Dokumentation der Fachtagung mit Präsentationen:
http://www.ages.at/ages/ages-akademie/stakeholderveranstaltungen/graz-listerien-referenzlabor/
"Listerien-Referenzlabor: Akademischer Luxus oder Public Health Erfordernis?", 19. Oktober 2012 (AGES, Graz)
Das Nationale Listerien-Referenzlabor ist innerhalb der AGES an das "Zentrum für lebensmittelbedingte Infektionskrankheiten" / Institut für medizinische Mikrobiologie und Hygiene in Graz übersiedelt. Zum Auftakt am neuen Standort veranstaltete die AGES dieses Fachgespräch, bei dem verschiedene Aspekte in Zusammenhang mit dem potentiellen Auftreten von Listerien aktuell beleuchtet wurden. Erstmals wurden zudem die neuen Richtlinien des Europäischen Referenzlabors (EU-RL) für Listeria monocytogenes zur Harmonisierung der Probennahme vorgestellt.
Dokumentation der Fachtagung mit Präsentationen:
http://www.ages.at/ages/ages-akademie/stakeholderveranstaltungen/graz-listerien-referenzlabor/
"Listerien-Referenzlabor: Akademischer Luxus oder Public Health Erfordernis?", 19. Oktober 2012 (AGES, Graz)
Das Nationale Listerien-Referenzlabor ist innerhalb der AGES an das "Zentrum für lebensmittelbedingte Infektionskrankheiten" / Institut für medizinische Mikrobiologie und Hygiene in Graz übersiedelt. Zum Auftakt am neuen Standort veranstaltete die AGES dieses Fachgespräch, bei dem verschiedene Aspekte in Zusammenhang mit dem potentiellen Auftreten von Listerien aktuell beleuchtet wurden. Erstmals wurden zudem die neuen Richtlinien des Europäischen Referenzlabors (EU-RL) für Listeria monocytogenes zur Harmonisierung der Probennahme vorgestellt.
Dokumentation der Fachtagung mit Präsentationen:
http://www.ages.at/ages/ages-akademie/stakeholderveranstaltungen/graz-listerien-referenzlabor/
More from AGES - Österreichische Agentur für Gesundheit und Ernährungssicherheit (20)
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
pathology MCQS introduction to pathology general pathology
"The new EURL Guidelines on sampling the food processing area and equipment for the detection of Listeria monocytogenes" - Léna Barre (ANSES, Frankreich)
1. European Union
Reference Laboratory
for Listeria
monocytogenes
EURL Guidelines for sampling food preparation
areas and equipment for L. monocytogenes
Léna BARRE & Brigitte CARPENTIER
French Agency for food, environmental & occupational health & safety
2. Context
• RTE foods can be contaminated during processing by
subtypes of Lm which persist in the processing plants
• Sampling processing is thus necessary & mandatory* to:
detect possible Lm persistence
eliminate it
implement corrective actions
*2073/2005, Article 5, paragraph 2:
“Samples shall be taken from processing areas and equipment used in food
production, when such sampling is necessary for ensuring that the criteria are met.
In that sampling the ISO standard 18593 shall be used as a reference method.
2
3. Context
• ISO 18593* on surface sampling methods does not give
sufficient guidance specific to Lm detection
• Great variety of sampling practices and some wrong
practices
Stress the urgent need for European guidelines
*“Microbiology of food and animal feeding stuffs -- Horizontal methods for
sampling techniques from surfaces using contact plates and swabs”
3
4. Context
FBOs WG NRLs
EURL Lm
Guidelines on sampling the food processing area &
equipment for the detection of Lm
4
5. Steps in the Guidelines production
1- Review the ISO 18593 Standard
2- Review the literature: need to add to the ISO Standard
specific guidance on sampling techniques for Lm control
3- Conduct a survey: EURL conducted enquiry to survey
the different practices in terms of environmental sampling
techniques
4- Publish the guidelines
5
6. Steps in the Guidelines production
1- Review the ISO 18593 Standard
2- Review the literature: need to add to the ISO Standard
specific guidance on sampling techniques for Lm control
3- Conduct a survey: EURL conducted enquiry to survey
the different practices in terms of environmental sampling
techniques
4- Publish the guidelines
6
7. ISO 18593
The ISO 18593* standard does not describe:
- when sampling should be performed
- what areas should be sampled
The standard ISO 18593 does not provide all the
necessary information
* ISO 18593 : “Microbiology of food and animal feeding stuffs -- Horizontal methods for
sampling techniques from surfaces using contact plates and swabs”
7
8. Steps in the Guidelines production
1- Review the ISO 18593 Standard
2- Review the literature : need to add to the ISO Standard
specific guidance on sampling techniques for Lm control
3- Conduct a survey: EURL conducted enquiry to survey
the different practices in terms of environmental sampling
techniques
4- Publish the guidelines
8
9. Review of the literature
ISO 18 593 FDA Guidance Other references
document (2008)
At least 100 Constant area as large 2000-5000 cm² (Tompkin,
Sampled cm2 preferably as possible 1999)
flat about 1000cm2 - 30-100 cm2 3716 cm2 (Mc Namara, 2007)
surface for sponging Up to 900 cm² (Canadian rec,
area 2010)
- 10-13 cm2 Up to 50 cm² (NSW, 2008)
for swabbing
After the Critical Food-Contact After minimum 3H
Time at disinfection Surfaces: production (Mc Namara,
which contact time both prior to cleanup 2007)
sampling to assess the & no sooner than the
should be performance of middle of production During or at the end of
performed the C &D production (Tompkin, 2004)
programme Critical Non-Food-
Contact Surfaces: During full production or
at any time before equipment clean-up
(NSW, 2008)
9
11. Review of the literature
Comparison of the requirements or recommendations on how to perform sampling of
surfaces including those specifically written for Lm
Main ideas:
Recommendations found in the literature are not all the same
Few published scientific papers reported on results obtained in field
conditions (Kovacevic et al; 2009)
FBOs have great experience in sampling surfaces for Lm detection and
that they do not publish their knowhow
Launching of a European survey to know how they proceed
11
12. Steps in the Guidelines production
1- Review the ISO 18593 Standard
2- Review the literature: need to add to the ISO Standard
specific guidance on sampling techniques for Lm control
3- Conduct a survey: EURL conducted enquiry to survey
the different practices in terms of environmental sampling
techniques
4- Publish the guidelines
12
13. European survey
The EURL conducted a survey in 2010 on the different
practices in terms of environmental sampling techniques
Enquiry into NRLs, competent authorities and FBOs
137 respondents, from 15 EU Member States
13
15. European survey
Swabs Brush & gauze pad
Dry (only in the event of an
alert, only one respondent)
+
wet
15
16. What scrubbing device(s) do you use?
3% 3% 1% gauze pad
5% wet cotton swab only
7% 29% multiple response
sponge
dry cotton swab only
16% ?
dry and wet swabs only
other
20%
16% brush
16
17. European survey
•• Several respondents declared wrong practices
Several respondents declared wrong practices
– sampling only after C&D,
– sampling only after C&D,
– sampling too small areas ...
– sampling too small areas ...
Emphases the need for European guidelines
Emphases the need for European guidelines
17
18. Steps in the Guidelines production
1- Review the ISO 18593 Standard
2- Review the literature: need to add to the ISO Standard
specific guidance on sampling techniques for Lm control
3- Conduct a survey: EURL conducted enquiry to survey
the different practices in terms of environmental sampling
techniques
4- Publish the guidelines
18
19. Steps in the Guidelines production
• March 2011
– Draft 1 sent to NRLs, each NRL circulated it to operators practicing
surface sampling
• September 2011
– 80 comments from 20 reviewers, Draft 2 sent to an European
working group of 20 people (Italy, Denmark, Portugal, Spain,
France, Ireland, Estonia)
• February 2012
– 90 comments from 13 reviewers, Draft 3 sent to the working
group
• March 2012
– 37 comments from 5 reviewers
– Draft 4 sent to the working group for a last discussion at a
web/phone meeting: version 0
– 28 March: NRLs approval version 1 19
20. Steps in the Guidelines production
• April – August 2012
version 3 which is available at:
http://www.ansespro.fr/eurl-listeria
20
21. The Guidelines
http://www.ansespro.fr/eurl-listeria
1. SCOPE
2. NORMATIVE REFERENCES
3. CHOICE OF SAMPLING LOCATIONS
4. TIME AT WHICH SAMPLING SHALL BE PERFORMED
5. DILUENTS TO MOISTEN THE WIPE SAMPLING DEVICES
6. CULTURE MEDIA
7. APPARATUS AND GLASSWARE
8. AREA TO BE SAMPLED
9. PREPARATION OF SAMPLING DEVICES
10.SAMPLING
11.TRANSPORT
12.SAMPLE ANALYSIS
13.EXPRESSION OF RESULTS
14.REFERENCES
21
22. Main differences: guidelines vs ISO 18593
1. SCOPE
– NOTE 2: No advice on
• sampling frequency
• number of sampling points
• validity of compositing (pooling) the samples
• necessity to rotate sampling points
they have to be chosen on a case-by-case basis, with a risk-based approach.
– NOTE 3: These guidelines are not designed to assess C&D
efficiency
2. CHOICE OF SAMPLING LOCATIONS
– A non-exhaustive list of places to choose sampling locations is
given quite similar to those of the FDA (2008) & NSW (2008)
doc.
22
23. Main differences: guidelines vs ISO 18593
3. TIME AT WHICH SAMPLING SHOULD BE
PERFORMED
– Sampling should be performed
• during processing
• after at least 2h of production
• or at the end of production runs
– When raw food is processed, sampling after
C&D or at the beginning of production can be
performed
• Yet, this can lead to a false sense of security
• The detection of L. monocytogenes on food-contact surfaces
after C&D indicates a serious failure in C&D procedures.
23
24. Main differences: guidelines vs ISO 18593
4. DILUENTS TO MOISTEN THE WIPE SAMPLING DEVICES
– No neutralizer when sampling during or at the end of
production except when residues of disinfectants are
expected
– Phosphate buffered diluents are not recommended
5. AREA TO BE SAMPLED
– hard-to-reach/small areas stick swabs
– large areas sponge, woven or unwoven cloth or
gauze pad
• The total sampled area should be as large as possible
• It is advised to sample between 1000 cm² and 3000 cm² when the areas
are open and flat (conveyors, shelves, etc.)
24
25. Main differences : guidelines vs ISO 18593
6. PREPARATION OF SAMPLING DEVICES
– No equipment which has been inside a microbiology
laboratory should be taken into a food production area
due to the risks of introducing contamination
– Operators should ensure that no item used for sampling
is left in the production area. For this purpose, counting
these items before and after sampling is recommended.
25
26. Main differences : guidelines vs ISO 18593
7. TRANSPORT, STORAGE, STARTING ANALYSIS
– Several reviewers asked for length of time longer than
24h before sample analysis (48h, 72h)
– Decision: Examine the samples ASAP, preferably not
later than 24h after receipt at the lab & in any case not
later than 36h after sampling (ISO 7218).
8. SAMPLE ANALYSIS
– ½ Fraser broth in the sampling device,
EN ISO 11290-1 or any alternative validated method
26
27. The shadows on the wall do not
make up reality at all
27
28. Next steps
• Analysis of the 2nd part of the survey on the
sample analysis, review of the literature and
decision whether there is a need for specific
recommendations, not included in the
EN ISO 11290-1&2 Standards
• Proposal : an experimental study to assess
– The impact of using a neutralizer on the probability to detect Lm
– The best diluent/neutralizer to avoid loss of culturability of
stressed Lm cells
– The best wiping device : sponge, woven on unwoven cloth,
gauze pad
– Etc.
28
29. IN COLLABORATION WITH
DENMARK
L. Gram
SPAIN
ESTONIA J. Canet Noguera
J. Toomas Kramarenko A. Español Pueyo
J. Lago
FRANCE J. Pardos Bosch
C. Dufour J. Sanchez Hernandez
T. Grégori
P. Leglise
N. Sanchez
V. Stahl PORTUGAL
H. da Silva Mateus Fernandes Guedes
A. L. Ferreira Tavares
IRELAND S. Orfão Ferraz
B. Hickey C. M. Pires Gomes
M. Sol
M. M. Tenreiro dos Santos Monteiro Saraiva
ITALY
S. Barbuti
UE DG-SANCO
29
30. References
ISO 18593. Microbiology of food and animal feeding stuffs -- Horizontal methods for sampling
techniques from surfaces using contact plates and swabs.
ISO 7218 Microbiology of food and animal feeding stuffs — General requirements and
guidance for microbiological examinations
FDA. 2008. Guidance for Industry: Control of Listeria monocytogenes in Refrigerated or
Frozen Ready-To-Eat Foods; Draft Guidance. U.S. Food and Drug Administration,
Department of Health and Human Services
http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/F
oodProcessingHACCP/ucm073110.htm, accessed 1 April 2010.
NSW. 2008. Food Authority for meat processors and retail meat licensees. Listeria
Management Program NSW/FA/FI034/0809.
http://www.foodauthority.nsw.gov.au/_Documents/industry_pdf/listeria-management-
program.pdf accessed 27 January 2011:40 pp.
http://www.ansespro.fr/eurl-listeria
30